<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450853</url>
  </required_header>
  <id_info>
    <org_study_id>GRA / SC-IV</org_study_id>
    <nct_id>NCT00450853</nct_id>
  </id_info>
  <brief_title>Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients</brief_title>
  <official_title>Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated With Platinum Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: to evaluate the bioavailability of subcutaneous granisetron.Patients receiving&#xD;
      platinum-based chemotherapy will be randomized to receive granisetron 3 mg either&#xD;
      subcutaneously or intravenously in a crossover manner during two cycles. Blood and urine&#xD;
      samples will be collected after each cycle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5-HT3 antagonists are one of the mainstays of antiemetic treatment and they are administered&#xD;
      either intravenously or orally. Nevertheless sometimes neither administration route is&#xD;
      feasible, such as in patients unable to admit oral intake managed in an outpatient setting.&#xD;
      Our objective is to evaluate the bioavailability of subcutaneous granisetron.Patients&#xD;
      receiving platinum-based chemotherapy will be randomized to receive granisetron 3 mg either&#xD;
      subcutaneously or intravenously in a crossover manner during two cycles. Blood and urine&#xD;
      samples will be collected after each cycle. Pharmacokinetics of SC and IV granisetron will be&#xD;
      prospectively compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>Approximately 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Approximately 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Granisetron SC-Granisetron IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Granisetron SC followed by Granisetron IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>granisetron</intervention_name>
    <description>Granisetron SC followed by granisetron IV</description>
    <arm_group_label>Granisetron SC-Granisetron IV</arm_group_label>
    <other_name>Granisetron SC followed by granisetron IV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cancer patients receiving platinum-based chemotherapy&#xD;
&#xD;
          -  adequate bone marrow, hepatic and renal function, respectively defined by: platelets&#xD;
             &gt;100000/mm3 and absolute neutrophil count &gt;1500/mm3; bilirubin, AST and ALT &lt;2 times x&#xD;
             upper limit of normality; and creatinine &lt;1.5 mg/dl.&#xD;
&#xD;
          -  ECOG performance status &lt;2 and body mass index from 20-28 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Serious concomitant diseases, in the invesgatorÂ´s criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso Gurpide</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Department. Clinica Universitaria de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>March 21, 2007</study_first_submitted>
  <study_first_submitted_qc>March 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinica Universidad de Navarra, Universidad de Navarra</investigator_affiliation>
    <investigator_full_name>Jose Luis Perez Gracia</investigator_full_name>
    <investigator_title>Main investigator</investigator_title>
  </responsible_party>
  <keyword>emesis</keyword>
  <keyword>granisetron</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>subcutaneous.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granisetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

